目的:观察补气益肺活血中药方辅助微创治疗肺癌的临床疗效。方法:选取2011年1月~2013年11月就诊于我院的非小细胞肺癌患者(NSCLC)共70例,采取随机数字表法分为实验组和对照组。对照组予以胸腔镜手术治疗,实验组在对照组基础上,术后予以为期6个月的益肺活血汤治疗。对比两组患者治疗前及治疗6个月后的外周血T细胞亚群及细胞因子水平、对比两组患者治疗6个月后的临床疗效。结果:两组患者治疗6个月后CD3+水平均显著高于治疗前,P<0.01,实验组患者治疗6个月后CD3+CD4+、CD3+CD8+、NK、NKT和Treg水平均显著高于治疗前,P<0.01;对照组患者治疗6个月后CD3+CD4+、CD3+CD8+、NK、NKT和Treg水平均显著低于治疗前及实验组治疗后,P<0.01。两组患者治疗6个月后s Fas水平均显著低于治疗前,P<0.01,实验组患者治疗6个月后IFN-γ、TNF-α、IL-2水平均显著高于治疗前,P<0.01;对照组患者治疗6个月后IFN-γ、TNF-α、IL-2水平均显著低于治疗前及实验组治疗后,P<0.01。实验组治疗6个月后有效率显著高于对照组,P<0.05。结论:采取补气益肺活血中药方辅助微创治疗肺癌临床疗效显著,可有效改善患者的术后免疫水平,值得临床应用。 Objective: To observe the clinical effects of Buqi Yifexhuoxue Auxiliary Minimally Invasive Treating Lung Cancer. Methods: Seventy patients with non-small cell lung cancer (NSCLC) visited our hospital from January 2011 to November 2013 were randomly divided into experimental group and control group. The control group was treated by thoracoscope surgery. The experimental group was given Yifeihuoxue Decoction for 6 months after operation on the basis of the control group. The levels of T lymphocyte subsets and cytokines in peripheral blood before treatment and after 6 months of treatment were compared between two groups, and the clinical efficacy was compared between the two groups after 6 months of treatment. Results: The levels of CD3 +, CD3 +, CD8 +, NK, NKT and Treg after 6 months of treatment in both groups were significantly higher than those before treatment (P <0.01). The levels of CD3 + CD4 +, CD3 + CD8 +, NK, NKT and Treg in the control group after 6 months of treatment were significantly lower than those before treatment and after the treatment in the experimental group (P <0.01). The levels of sFas in both groups after 6 months of treatment were significantly lower than those before treatment (P <0.01). The levels of IFN-γ, TNF-α and IL-2 in experimental group were significantly higher than those before treatment <0.01; The levels of IFN-γ, TNF-α and IL-2 in the control group after 6 months treatment were significantly lower than those before treatment and after treatment in the experimental group (P <0.01). The experimental group after 6 months of treatment efficiency was significantly higher than the control group, P <0.05. Conclusion: The clinical curative effect of Buqi Yihuohuoxue Chinese herbal medicine for minimally invasive treatment of lung cancer is significant, which can effectively improve the postoperative immunity of patients and is worthy of clinical application.